Characteristics of Ibritumomab as Radionuclide Therapy Agent
Crossref DOI link: https://doi.org/10.1007/978-3-319-78238-6_6
Published Online: 2018-04-25
Published Print: 2018
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kawashima, Hidekazu
License valid from 2018-01-01